Centre Hospitalier Schaffner France Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
1999
NCT00169130
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

Centre Hospitalier Schaffner, Lens FRANCE | National Co-Coordinating Investigator - Centre Hospitalier Schaffner France (Lens cedex)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Waldenstrom Macroglobulinemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 6